1. Home
  2. EARN vs CNTX Comparison

EARN vs CNTX Comparison

Compare EARN & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

N/A

Current Price

$5.09

Market Cap

200.3M

Sector

Real Estate

ML Signal

N/A

Logo Context Therapeutics Inc.

CNTX

Context Therapeutics Inc.

N/A

Current Price

$2.26

Market Cap

209.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EARN
CNTX
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
200.3M
209.5M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
EARN
CNTX
Price
$5.09
$2.26
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$5.88
$6.00
AVG Volume (30 Days)
526.0K
1.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
18.90%
N/A
EPS Growth
N/A
69.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.43
N/A
Revenue Next Year
$17.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.33
$0.49
52 Week High
$6.50
$2.85

Technical Indicators

Market Signals
Indicator
EARN
CNTX
Relative Strength Index (RSI) 37.61 60.50
Support Level $5.06 $2.06
Resistance Level $5.36 $2.58
Average True Range (ATR) 0.11 0.18
MACD -0.01 -0.03
Stochastic Oscillator 27.03 63.27

Price Performance

Historical Comparison
EARN
CNTX

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Share on Social Networks: